Reproductive hormone sensitivity and risk for depression across the female life cycle: A continuum of vulnerability?

Journal of Psychiatry and Neuroscience

Volumn 33, Issue 4, 2008, Pages 331-343

  Soares, Claudio N ^a   Zitek, Brook ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b PFIZER INC   (United States)

Author keywords

Depression; Estrogens; Hormone replacement therapy; Menopause; Pregnancy; Premenstrual syndrome

Indexed keywords

ANTIDEPRESSANT AGENT; ESTRADIOL; ESTRADIOL BENZOATE; ESTRADIOL VALERATE; ESTROGEN; FOLLITROPIN; GESTAGEN; MEDROXYPROGESTERONE; NEUROTRANSMITTER; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PRASTERONE; PROGESTERONE; RALOXIFENE; SEROTONIN; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN; TESTOSTERONE;

ADRENALECTOMY; ANXIETY; BIOAVAILABILITY; CHILD DEVELOPMENT; CLIMACTERIUM; CLINICAL ASSESSMENT; CLINICAL TRIAL; COGNITIVE DEVELOPMENT; COMORBIDITY; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; DEPRESSION; DYSTHYMIA; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; HAZARD RATIO; HORMONAL THERAPY; HORMONE ACTION; HORMONE SENSITIVITY; HUMAN; LANGUAGE DISABILITY; LIFE CYCLE; LONG TERM CARE; MAJOR DEPRESSION; MENOPAUSAL SYNDROME; MENSTRUAL CYCLE; MOOD; MOOD DISORDER; NONHUMAN; OVARIECTOMY; OVARY CYCLE; PREGNANCY; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PREVALENCE; PROGESTERONE BLOOD LEVEL; PUERPERAL DEPRESSION; QUALITY OF LIFE; QUALITY OF LIFE INDEX; RISK; RISK ASSESSMENT; RISK FACTOR; SOCIAL PSYCHOLOGY; SOMATOFORM DISORDER; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VULNERABLE POPULATION; WOMEN'S HEALTH;

EID: 47149084197     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (153)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105.
2. Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996;276:293-9.
3. Kessler RC, McGonagle KA, Swartz M, et al. Sex and depression in the National Comorbidity Survey. I: lifetime prevalence, chronicity and recurrence. J Affect Disord 1993;29:85-96.
4. Arpels JC. The female brain hypoestrogenic continuum from the premenstrual syndrome to menopause. A hypothesis and review of supporting data. J Reprod Med 1996;41:633-9.
5. Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry 1998;44:839-50.
6. Cyranowski JM, Frank E, Young E, et al. Adolescent onset of the gender difference in lifetime rates of major depression: a theoretical model. Arch Gen Psychiatry 2000;57:21-7.
7. Robichaud M, Debonnel G. Oestrogen and testosterone modulate the firing activity of dorsal raphe nucleus serotonergic neurones in both male and female rats. J Neuroendocrinal 2005;17:179-85.
8. Bethea CL, Mirkes SJ, Shively CA, et al. Steroid regulation of tryptophan hydroxylase protein in the dorsal raphe of macaques. Biol Psychiatry 2000;47:562-76.
9. Pecins-Thompson M, Brown NA, Kohama SG, et al. Ovarian steroid regulation of tryptophan hydroxylase mRNA expression in rhesus macaques. J Neurosci 1996;16:7021-9.
10. Smith LJ, Henderson JA, Abell CW, et al. Effects of ovarian steroids and raloxifene on proteins that synthesize, transport, and degrade serotonin in the raphe region of macaques. Neuropsychopharmacology 2004;29:2035-45.
11. Mize AL, Young LJ, Alper RH. Uncoupling of 5-HT1A receptors in the brain by estrogens: regional variations in antagonism by ICI 182,780. Neuropharmacology 2003;44:584-91.
12. Sumner BE, Fink G. Testosterone as well as estrogen increases serotonin2A receptor mRNA and binding site densities in the male rat brain. Brain Res Mol Brain Res 1998;59:205-14.
13. Raap DK, DonCarlos LL, Garcia F, et al. Ovariectomy-induced increases in hypothalamic serotonin-1A receptor function in rats are prevented by estradiol. Neuroendocrinology 2002;76:348-56.
14. Pau KY, Hess DL, Kohama S, et al. Oestrogen upregulates noradrenaline release in the mediobasal hypothalamus and tyrosine hydroxylase gene expression in the brainstem of ovariectomized rhesus macaques. J Neuroendocrinal 2000;12:899-909.
15. Panek DU, Dixon WR. Effect of continuous intraventricular estrogen or catechol estrogen treatment on catecholamine turnover in various brain regions. J Pharmacol Exp Ther 1986;236:646-52.
16. Petitti N, Etgen AM. Alpha 1-adrenoceptor augmentation of beta-stimulated cAMP formation is enhanced by estrogen and reduced by progesterone in rat hypothalamic slices. J Neurosci 1990;10:2842-9.
17. Karkanias GB, Etgen AM. Estradiol attenuates alpha 2-adrenoceptor- mediated inhibition of hypothalamic norepinephrine release. J Neurosci 1993;13:3448-55.
18. Ansonoff MA, Etgen AM. Evidence that oestradiol attenuates beta-adrenoceptor function in the hypothalamus of female rats by altering receptor phosphorylation and sequestration. J Neuroendocrinol 2000;12:1060-6.
19. Karkanias GB, Ansonoff MA, Etgen AM. Estradiol regulation of alpha 1b-adrenoceptor mRNA in female rat hypothalamus-preoptic area. J Neuroendocrinol 1996;8:449-55.
20. Clarke IJ, Scott CJ, Pereira A, et al. Levels of dopamine beta hydroxylase immunoreactivity in the preoptic hypothalamus of the ovariectomised ewe following injection of oestrogen: evidence for increased noradrenaline release around the time of the oestrogen-induced surge in luteinizing hormone. J Neuroendocrinal 1999;11:503-12.
21. Velisek L, Veliskova J. Estrogen treatment protects GABA(B) inhibition in the dentate gyrus of female rats after kainic acid-induced status epilepticus. Epilepsia 2002;43(Suppl 5):146-51.
22. Schumacher M, Coirini H, McEwen BS. Regulation of high-affinity GABAA receptors in the dorsal hippocampus by estradiol and progesterone. Brain Res 1989;487:178-83.
23. Jussofie A, Korner I, Schell C, et al. Time course of the effects of steroid hormone deprivation elicited by ovariectomy or ovariectomy plus adrenalectomy on the affinity and density of GABA binding sites in distinct rat brain areas. Exp Clin Endocrinol Diabetes 1995;103:196-204.
24. O'Connor LH, Nock B, McEwen BS. Regional specificity of gamma-aminobutyric acid receptor regulation by estradiol. Neuroendocrinology 1988;47:473-81.
25. Murphy DD, Cole NB, Greenberger V, et al. Estradiol increases dendritic spine density by reducing GABA neurotransmission in hippocampal neurons. J Neurosci 1998;18:2550-9.
26. Bazzett TJ, Becker JB. Sex differences in the rapid and acute effects of estrogen on striatal D2 dopamine receptor binding. Brain Res 1994;637:163-72.
27. Tinkler GP, Tobin JR, Voytko ML. Effects of two years of estrogen loss or replacement on nucleus basalis cholinergic neurons and cholinergic fibers to the dorsolateral prefrontal and inferior parietal cortex of monkeys. J Comp Neurol 2004;469:507-21.
28. Shughrue PJ, Scrimo PJ, Merchenthaler 1. Estrogen binding and estrogen receptor characterization (ERalpha and ERbeta) in the cholinergic neurons of the rat basal forebrain. Neuroscience 2000;96:41-9.
29. Nilsen J, Chen S, Brinton RD. Dual action of estrogen on glutamate-induced calcium signaling: mechanisms requiring interaction between estrogen receptors and src/mitogen activated protein kinase pathway. Brain Res 2002;930:216-34.
30. Wihlback AC, Sundstrom-Poromaa I, Allard P, et al. Influence of postmenopausal hormone replacement therapy on platelet serotonin uptake site and serotonin 2A receptor binding. Obstet Gynecol 2001;98:450-7.
31. Gregoire AJ, Kumar R, Everitt B, et al. Transdermal oestrogen for treatment of severe postnatal depression. Lancet 1996;347:930-3.
32. Hlatky MA, Boothroyd D, Vittinghoff E, et al. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 2002;287:591-7.
33. Halbreich U, Rojansky N, Palter S, et al. Estrogen augments serotonergic activity in postmenopausal women. Biol Psychiatry 1995;37:434-41.
34. Soares CN, Almeida OP, Joffe H, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001;58:529-34.
35. Morrison MF, Kalian MJ, Ten Have T, et al. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry 2004;55:406-12.
36. Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000;183:414-20.
37. Kugaya A, Epperson CN, Zoghbi S, et al. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry 2003;160:1522-4.
38. Gundlah C, Lu NZ, Bethea CL. Ovarian steroid regulation of monoamine oxidase-A and -B mRNAs in the macaque dorsal raphe and hypothalamic nuclei. Psychopharmacology (Berl) 2002;160:271-82.
39. Kaura V, Ingram CD, Gartside SE, et al. The progesterone metabolite allopregnanolone potentiates GABA(A) receptor-mediated inhibition of 5-HT neuronal activity. Eur Neuropsychopharmacol 2007;17:108-15.
40. Karkanias GB, Petitti N, Etgen AM. Progesterone attenuation of alpha 1-adrenergic receptor stimulation of phosphoinositol hydrolysis in hypothalamus of estrogen-primed female rats. Endocrinology 1995;136:1993-9.
41. Bitran D, Shiekh M, McLeod M. Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABAA receptors. J Neuroendocrinol 1995;7:171-7.
42. Weiland NG, Orchinik M. Specific subunit mRNAs of the GABAA receptor are regulated by progesterone in subfields of the hippocampus. Brain Res Mol Brain Res 1995;32:271-8.
43. Rapkin AJ, Morgan M, Goldman L, et al. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 1997;90:709-14.
44. Monteleone P, Luisi S, Tonetti A, et al. Allopregnanolone concentrations and premenstrual syndrome. Eur J Endocrinol 2000;142:269-73.
45. Bicikova M, Tallova J, Hill M, et al. Serum concentrations of some neuroactive steroids in women suffering from mixed anxiety-depressive disorder. Neurochem Res 2000;25:1623-7.
46. Baker ER, Best RG, Manfredi RL, et al. Efficacy of progesterone vaginal suppositories in alleviation of nervous symptoms in patients with premenstrual syndrome. J Assist Reprod Genet 1995;12:205-9.
47. Freeman EW, Purdy RH, Coutifaris C, et al. Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers. Neuroendocrinology 1993;58:478-84.
48. Zhang L, Ma W, Barker JL, et al. Sex differences in expression of serotonin receptors (subtypes 1A and 2A) in rat brain: a possible role of testosterone. Neuroscience 1999;94:251-9.
49. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-8.
50. Barrett-Connor E, von Muhlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab 1999;84:573-7.
51. Weber B, Lewicka S, Deuschle M, et al. Testosterone, androstenedione and dihydrotestosterone concentrations are elevated in female patients with major depression. Psychoneuroendocrinology 2000;25:765-71.
52. Santoro N, Torrens J, Crawford S, et al. Correlates of circulating androgens in mid-life women: the study of women's health across the nation. J Clin Endocrinol Metab 2005;90:4836-45.
53. Robichaud M, Debonnel G. Modulation of the firing activity of female dorsal raphe nucleus serotonergic neurons by neuroactive steroids. J Endocrinol 2004;182:11-21.
54. Majewska MD, Demirgoren S, Spivak CE, et al. The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor. Brain Res 1990;526:143-6.
55. Demirgoren S, Majewska MD, Spivak CE, et al. Receptor binding and electrophysiological effects of dehydroepiandrosterone sulfate, an antagonist of the GABAA receptor. Neuroscience 1991;45:127-35.
56. Yaffe K, Ettinger B, Pressman A, et al. Neuropsychiatric function and dehydroepiandrosterone sulfate in elderly women: a prospective study. Biol Psychiatry 1998;43:694-700.
57. Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999;156:646-9.
58. Bloch M, Schmidt PJ, Danaceau MA, et al. Dehydroepiandrosterone treatment of midlife dysthymia. Biol Psychiatry 1999;45:1533-41.
59. Barrett-Connor E, von Muhlen D, Laughlin GA, et al. Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study. J Am Geriatr Soc 1999;47:685-91.
60. Wolkowitz OM, Reus VI, Roberts E, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry 1997;41:311-8.
61. Schmidt PJ, Nieman LK, Danaceau MA, et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998;338:209-16.
62. Bloch M, Schmidt PJ, Danaceau M, et al. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry 2000;157:924-30.
63. Morrison JH, Brinton RD, Schmidt PJ, et al. Estrogen, menopause, and the aging brain: how basic neuroscience can inform hormone therapy in women. J Neurosci 2006;26:10332-48.
64. McEwen BS, Milner TA. Hippocampal formation: shedding light on the influence of sex and stress on the brain. Brain Res Rev 2007;55:343-55.
65. Freeman EW, Sammel MD, Liu L, et al. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004;61:62-70.
66. Schmidt PJ, Daly RC, Bloch M, et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 2005;62:154-62.
67. Kronenberg F. Hot flashes: phenomenology, quality of life, and search for treatment options. Exp Gerontol 1994;29:319-36.
68. Barton D, Loprinzi C, Wahner-Roedler D. Hot flashes: aetiology and management. Drugs Aging 2001;18:597-606.
69. Berendsen HHG. The role of serotonin in hot flushes. Maturitas 2000;36:155-64.
70. Tan KS, McFarlane LC, Lipworth BJ. Paradoxical down-regulation and desensitization of beta2-adrenoceptors by exogenous progesterone in female asthmatics. Chest 1997;111:847-51.
71. Brandes JL. The influence of estrogen on migraine: a systematic review. JAMA 2006;295:1824-30.
72. Cohen LS, Soares CN, Otto MW, et al. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles. J Affect Disord 2002;70:125-32.
73. Perkonigg A, Yonkers KA, Pfister H, et al. Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder. J Clin Psychiatry 2004;65:1314-22.
74. Field T, Hernandez-Reif M, Diego M. Risk factors and stress variables that differentiate depressed from nondepressed pregnant women. Infant Behav Dev 2006;29:169-74.
75. Rubertsson C, Wickberg B, Gustavsson P, et al. Depressive symptoms in early pregnancy, two months and one year postpartum-prevalence and psychosocial risk factors in a national Swedish sample. Arch Womens Ment Health 2005;8:97-104.
76. Bromberger JT, Matthews KA, Schott LL, et al. Depressive symptoms during the menopausal transition: the Study of Women's Health Across the Nation (SWAN). J Affect Disord 2007;103:267-72.
77. Rapkin AJ, Mikacich JA, Moatakef-Imani B, et al. The clinical nature and formal diagnosis of premenstrual, postpartum, and perimenopausal affective disorders. Curr Psychiatry Rep 2002;4:419-28.
78. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington: The Association; 1994.
79. Thys-Jacobs S, McMahon D, Bilezikian JP. Differences in free estradiol and sex hormone binding globulin in women with and without premenstrual dysphoric disorder. J Clin Endocrinol Metab 2007;93:96-102
80. Coffee AL, Kuehl TJ, Willis S, et al. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol 2006;195:1311-9.
81. Kroll R, Rapkin AJ. Treatment of premenstrual disorders. J Reprod Med 2006;51(Suppl):359-70.
82. Joffe H, Cohen LS, Harlow BL. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol 2003;189:1523-30.
83. Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001;10:561-9.
84. Pearlstein TB, Bachmann GA, Zacur HA, et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005;72:414-21.
85. Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005;106:492-501.
86. Ashby CR Jr, Carr LA, Cook CL, et al. Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome. Biol Psychiatry 1988;24:225-33.
87. Rapkin AJ, Edelmuth E, Chang LC, et al. Whole-blood serotonin in premenstrual syndrome. Obstet Gynecol 1987;70:533-7.
88. Jovanovic H, Cerin A, Karlsson P, et al. PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria. Psychiatry Res 2006;148:185-93.
89. Steiner M. Premenstrual syndrome and premenstrual dysphoric disorder: guidelines for management. J Psychiatry Neurosci 2000;25:459-68.
90. Steiner M, Hirschberg AL, Bergeron R, et al. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am J Obstet Gynecol 2005;193:352-60.
91. Freeman EW, Sondheimer SJ, Sammel MD, et al. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. J Clin Psychiatry 2005;66:769-73.
92. Johnson SR, McChesney C, Bean JA. Epidemiology of premenstrual symptoms in a nonclinical sample. I. Prevalence, natural history and help-seeking behavior. J Reprod Med 1988;33:340-6.
93. Rivera-Tovar AD, Frank E. Late luteal phase dysphoric disorder in young women. Am J Psychiatry 1990;147:1634-6.
94. Wittchen HU, Becker E, Lieb R, et al. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002;32:119-32.
95. Bailey JW, Cohen LS. Prevalence of mood and anxiety disorders in women who seek treatment for premenstrual syndrome. J Womens Health Gend Based Med 1999;8:1181-4.
96. Joffe H, Petrillo L, Viguera A, et al. Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: A preliminary report. J Clin Psychiatry 2007;1954-62.
97. Klink R, Robichaud M, Debonnel G. Gender and gonadal status modulation of dorsal raphe nucleus serotonergic neurons. Part I: effects of gender and pregnancy. Neuropharmacology 2002;43:1119-28.
98. Bennett HA, Einarson A, Taddio A, et al. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004;103:698-709.
99. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006;295:499-507.
100. Hallberg P, Sjoblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. J Clin Psychopharmacol 2005;25:59-73.
101. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-87.
102. Bonari L, Bennett H, Einarson A, et al. Risks of untreated depression during pregnancy. Can Fam Physician 2004;50:37-9.
103. Chung TK, Lau TK, Yip AS, et al. Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med 2001;63:830-4.
104. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002;159:1889-95.
105. Rubinow DR. Antidepressant treatment during pregnancy: between Scylla and Charybdis. Am J Psychiatry 2006;163:954-6.
106. Einarson A, Koren G. Prescribing antidepressants to pregnant women: What is a family physician to do? Can Fam Physician 2007;53:1412-5.
107. Alwan S, Reefhuis J, Rasmussen SA, et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356:2684-92.
108. Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675-83.
109. Jones I, Hamshere M, Nangle JM, et al. Bipolar affective puerperal psychosis: genome-wide significant evidence for linkage to chromosome 16. Am J Psychiatry 2007;164:1099-104.
110. Ahokas A, Kaukoranta J, Wahlbeck K, et al. Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17beta-estradiol: a preliminary study. J Clin Psychiatry 2001;62:332-6.
111. Josefsson A, Berg G, Nordin C, et al. Prevalence of depressive symptoms in late pregnancy and postpartum. Acta Obstet Gynecol Scand 2001;80:251-5.
112. Kitamura T, Yoshida K, Okano T, et al. Multicentre prospective study of perinatal depression in Japan: incidence and correlates of antenatal and postnatal depression. Arch Womens Ment Health 2006;9:121-30.
113. Lee DT, Chan SS, Sahota DS, et al. A prevalence study of antenatal depression among Chinese women. J Affect Disord 2004;82:93-9.
114. Rich-Edwards JW, Kleinman K, Abrams A, et al. Sociodemographic predictors of antenatal and postpartum depressive symptoms among women in a medical group practice. J Epidemiol Community Health 2006;60:221-7.
115. Bloch M, Rotenberg N, Koren D, et al. Risk factors for early postpartum depressive symptoms. Gen Hasp Psychiatry 2006;28:3-8.
116. Heron J, O'Connor TG, Evans J, et al. The course of anxiety and depression through pregnancy and the postpartum in a community sample. J Affect Disord 2004;80:65-73.
117. Bloch M, Rotenberg N, Koren D, et al. Risk factors associated with the development of postpartum mood disorders. J Affect Disord 2005;88:9-18.
118. Santoro N. The menopausal transition. Am J Med 2005;118(Suppl 12B):8-13.
119. Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril 2001;76:874-8.
120. Randolph JF Jr, Sowers M, Bondarenko IV, et al. Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age. J Clin Endocrinol Metab 2004;89:1555-61.
121. Randolph JF Jr, Crawford S, Dennerstein L, et al. The value of follicle-stimulating hormone concentration and clinical findings as markers of the late menopausal transition. J Clin Endocrinol Metab 2006;91:3034-40.
122. Charkoudian N. Skin blood flow in adult human thermoregulation: how it works, when it does not, and why. Mayo Clin Proc 2003;78:603-12.
123. Freeman EW, Sammel MD, Lin H, et al. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006;63:375-82.
124. Soares CN, Prouty J, Born L, et al. Treatment of menopause-related mood disturbances. CNS Spectr 2005;10:489-97.
125. Soares CN. Menopausal transition and depression: who is at risk and how to treat it? Expert Rev Neurother 2007;7:1285-93.
126. Arlt W. Androgen therapy in women. Eur J Endocrinol 2006;154:1-11.
127. Freedman MA. Quality of life and menopause: the role of estrogen. J Womens Health (Larchmt) 2002;11:703-18.
128. Davison SL, Bell R, Donath S, et al. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005;90:3847-53.
129. Gallicchio L, Whiteman MK, Tomic D, et al. Type of menopause, patterns of hormone therapv use, and hot flashes. Fertil Steril 2006;85:1432-40.
130. Woods NF, Mariella A, Mitchell ES. Depressed mood symptoms during the menopausal transition: observations from the Seattle Midlife Women's Health Study. Climacteric 2006;9:195-203.
131. Schmidt PJ, Haq N, Rubinow DR. A longitudinal evaluation of the relationship between reproductive status and mood in perimenopausal women. Am J Psychiatry 2004;161:2238-44.
132. Avis NE, Brambilla D, McKinlay SM, et al. A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women's Health Study. Ann Epidemiol 1994;4:214-20.
133. Richards M, Rubinow DR, Daly RC, et al. Premenstrual symptoms and perimenopausal depression. Am J Psychiatry 2006;163:133-7.
134. Cohen LS, Soares CN, Vitonis AF, et al. Risk for new onset of depression during the menopausal transition: The Harvard Study of Moods and Cycles. Arch Gen Psychiatry 2006;63:385-90.
135. Joffe H, Hall JE, Soares CN, et al. Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause 2002;9:392-8.
136. Stewart DE, Boydell KM. Psychologic distress during menopause: associations across the reproductive life cycle. Int J Psychiatry Med 1993;23:157-62.
137. Gregory RJ, Masand PS, Yohai NH. Depression across the reproductive life cycle: correlations between events. Prim Care Companion J Clin Psychiatry 2000;2:127-9.
138. Soares CN, Cohen LS, Otto MW, et al. Characteristics of women with premenstrual dysphoric disorder (PMDD) who did or did not report history of depression: a preliminary report from the Harvard Study of Moods and Cycles. J Womens Health Gend Based Med 2001;10:873-8.
139. Cohen LS, Soares CN, Poitras JR, et al. Short-term use of estradiol for depression in perimenopausal and postmenopausal women: a preliminary report. Am J Psychiatry 2003;160:1519-22.
140. Soares CN, Arsenio H, Joffe H, et al. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life. Menopause 2006;13:780-6.
141. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 1995;332:1529-34.
142. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 1997;278:983-8.
143. Cohen LS, Miner C, Brown EW, et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 2002;100:435-44.
144. Cassano P, Soares CN, Cusin C, et al. Antidepressant response and well-being in pre-, peri- and postmenopausal women with major depressive disorder treated with fluoxetine. Psychother Psychosom 2005;74:362-5.
145. Pinto-Meza A, Usall J, Serrano-Blanco A, et al. Gender differences in response to antidepressant treatment prescribed in primary care. Does menopause make a difference? J Affect Disord 2006;93:53-60.
146. Thase ME, Entsuah R, Cantillon M, et al. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health (Larchmt) 2005;14:609-16.
147. Soares CN, Poitras JR, Prouty J, et al. Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. J Clin Psychiatry 2003;64:473-9.
148. Rasgon N, Shelton S, Halbreich U. Perimenopausal mental disorders: epidemiology and phenomenology. CNS Spectr 2005;10:471-8.
149. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry 1987;150:782-6.
150. Greene JG. Constructing a standard climacteric scale. Maturitas 1998;29:25-31.
151. Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24:161-75.
152. Utian WH, Janata JW, Kingsberg SA, et al. The Utian Quality of Life (UQOL) Scale: development and validation of an instrument to quantify quality of life through and beyond menopause. Menopause 2002;9:402-10.
153. Kornstein SG. Gender differences in depression: implications for treatment. J Clin Psychiatry 1997;58(Suppl 15):12-8.